These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Spalding AC; Daignault S; Sandler HM; Shah RB; Pan CC; Ray ME Urology; 2007 May; 69(5):936-40. PubMed ID: 17482938 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706 [TBL] [Abstract][Full Text] [Related]
4. Percentage of tumor and tumor length in prostate biopsy specimens: a study of American veterans. Vollmer RT Am J Clin Pathol; 2008 Dec; 130(6):940-3. PubMed ID: 19019772 [TBL] [Abstract][Full Text] [Related]
5. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. Loeb S; Roehl KA; Thaxton CS; Catalona WJ Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287 [TBL] [Abstract][Full Text] [Related]
6. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303 [TBL] [Abstract][Full Text] [Related]
7. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691 [TBL] [Abstract][Full Text] [Related]
9. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695 [TBL] [Abstract][Full Text] [Related]
10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
11. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Nanda A; Chen MH; Renshaw AA; D'Amico AV Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185 [TBL] [Abstract][Full Text] [Related]
12. Percentage of tumor in prostatectomy specimens: a study of American Veterans. Vollmer RT Am J Clin Pathol; 2009 Jan; 131(1):86-91. PubMed ID: 19095570 [TBL] [Abstract][Full Text] [Related]
13. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477 [TBL] [Abstract][Full Text] [Related]
14. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700 [TBL] [Abstract][Full Text] [Related]
15. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related]
17. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer. Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349 [TBL] [Abstract][Full Text] [Related]
18. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847 [TBL] [Abstract][Full Text] [Related]
19. Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia. Brimo F; Vollmer RT; Corcos J; Humphrey PA; Bismar TA Am J Clin Pathol; 2007 Oct; 128(4):648-51. PubMed ID: 17875517 [TBL] [Abstract][Full Text] [Related]
20. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]